Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FIVE-STAR finerenone mechanistic trial in type 2 diabetes and chronic kidney disease
jRCTs021230011Completed
- Sponsor
- Bayer
- Start
- Sep 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial in type 2 diabetes mellitus (T2DM) and chronic kidney disease (CKD) comparing Finerenone with Placebo (2 arms). Primary endpoint: Change in cardio-ankle vascular index at 24 weeks. Started Sep 2023; status: completed.
02
Drugs
finerenone
03
Conditions
type 2 diabetes mellitus (T2DM)chronic kidney disease (CKD)
Beyond the preview
Go deeper on jRCTs021230011.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs021230011.